Manila Times Business
ITM Announces Phase 3 COMPETE Patient-Reported Quality of Life Data with n.c.a. ¹⁷⁷Lu-edotreotide (ITM-11) vs. Everolimus at ASCO 2026
¹⁷⁷Exploratory analysis showed favorable patient-reported quality of life outcomes and delayed time to deterioration in patients receiving ¹⁷⁷Lu-edotreotide Data build upon previously reported COMPETE efficacy results, adding patient-centered evidence for ¹⁷⁷Lu-edotreotide in GEP-NETsChicago, Illinois, May 30, 2026 -- ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced encouraging Health-Related Quality of Life (HRQoL) data from its Phase 3 CO
This is an excerpt. Read the full article at the original source:
Source: manilatimes.net
Read Full Article on manilatimes.net →More from Manila Times Business
Typhoon Domeng less likely to make landfall, to exit PAR Monday —Pagasa
2h ago
National Champions are Honoured at the Closing Ceremony of the Skills Canada National Competition 2026, in Toronto
2h ago
Take Your Shot & Make Your Moment: OPPO Ignites Football Culture with Technology at the UEFA Champions League Final
2h ago
ThinkCareBelieve: Week 71 of the Trump Administration 2.0
3h ago